International Psoriasis Council

Advancing Knowledge. Improving Care.

Vermen

Verallo-Rowell

,

MD, FPDS, FDSP-PDS, FAAD, FASDP, IHM-ADA 

Program Director
VMV Skin Research Centre + Clinics
Makati
,
Philippines
Councilor Since: November 1, 2012
IPC Councilor
Dr. Vermen M. Verallo-Rowell is a dermatologist based in the Philippines, founder of the Philippine Photodermatology and Contact Dermatology Societies, and a founding member of the Asian Society of Dermatopathology. She is actively engaged in clinical research through the Center for Clinical Research, Testing, and Product Development (CSRTPD-VSRC).



She has authored over 200 publications, including journal articles, book chapters, and two books focused on Skin in the Tropics. Her recent research, presented at the March 2025 Photodermatology Society Meeting in Orlando, Florida, introduced findings from an Individual Typology Angle (ITA°) spectrophotometry study, which revealed that Filipinos, similar to populations in other Southeast Asian Island nations, spanned Fitzpatrick Phototypes I to VI.

Dr. Verallo-Rowell serves as Senior Advisor to the Department of Dermatology at Makati Medical Center, Chair of the Skin and Cancer Foundation, Inc. (SCFI), and, as of 2023, Chair of the Dermatology Section at the V. Luna General Hospital – Armed Forces of the Philippines Medical Center. She is also a frequent speaker at regional dermatology meetings across Asia.

Dr. Verallo-Rowell is a member of the Asian Regional Psoriasis Forum, serves as Global Psoriasis Atlas (GPA) Regional Coordinator for the Western Pacific, and is a Councilor of the International Psoriasis Council (IPC). Together with fellow Philippine IPC Councilors Dr. Victoria Patiño Guillano and Dr. Patricia Anne Ty-Tinio, she co-led the project, Real-world Evidence from a Cluster Survey of Patients Guided by Multi-Center Dermatologists Toward the Philippine Psoriasis Registry, published in the November 2024 issue of the Journal of the Philippine Dermatological Society and featured in the January 2025 GPA Newsletter.
Last Updated:
07/11/2025

IPC Committees / Groups

Diverse Skin Types Working Group

Languages Spoken

English

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026